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What is already known about this subject? 
- Whilst severe obesity clearly increases the risk of death, there have been inconsistencies within the 
current literature relating to the "obesity paradox", whereby being overweight can appear seemingly 
protective. 
- Many studies also report a characteristic J-shaped curve in the association between body mass index 
and the risk of mortality from varying causes; however, there are discrepancies with the reporting of this 
pattern. 
- Mendelian randomization is a well-documented approach that uses genetic variation to provide a 
relatively unbiased causal estimate of the effect of an exposure on an outcome, overcoming limitations 
inherent in these observational studies. Yet, no study has explicitly used this technique to explore the 
causal role of body mass index in all-cause and cause-specific mortality.  
 
What does this study add? 
- We used Mendelian randomization to generate estimates of the causal role of body mass index in both 
all-cause and cause-specific mortality within the UK Biobank study, a powerful and large resource of 
comprehensive phenotypic, genetic and death registry data from the UK. 
- Results supported the causal role of higher body mass index in increasing the risk of all-cause mortality 
and mortality specifically from cardiovascular diseases, various cancers and other causes. Whilst the 
characteristic J-shaped observational association between body mass index and mortality was visible 
with Mendelian randomization analyses, the apparent optimum body mass index for survival was lower 
and the association remained flatter over a larger range of body mass index. 
- Our results further highlight the need for a global effort to reduce the rising population trends for excess 
weight and suggest that in most cases, any reduction in BMI is likely beneficial.  
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Abstract 
Objective: Obtain estimates of the causal relationship between body mass index (BMI) and mortality. 
Methods: Mendelian randomization (MR) using BMI-associated genotypic variation to test the causal 
effect of BMI on all-cause and cause-specific mortality in UK Biobank participants of White British 
ancestry. 
Results: MR analyses supported a causal association between higher BMI and greater risk of all-cause 
mortality (hazard ratio (HR) per 1kg/m2: 1.03; 95% CI: 0.99,1.07) and mortality from cardiovascular 
diseases (HR: 1.10; 95% CI: 1.01,1.19), specifically coronary heart disease (CHD; HR: 1.12; 95% CI: 
1.00,1.25) and those excluding CHD/stroke/aortic aneurysm, stomach cancer (HR: 1.18; 95% CI: 
0.87,1.62) and oesophageal cancer (HR: 1.22; 95% CI: 0.98,1.53), and decreased risk of lung cancer 
mortality (HR: 0.96; 95% CI: 0.85,1.08). Sex-stratification supported the causal role of higher BMI 
increasing bladder cancer mortality risk (males) but decreasing respiratory disease mortality risk 
(males). The J-shaped observational association between BMI and mortality was visible with MR analyses 
but the BMI at which mortality was minimised was lower and the association was flatter over a larger 
BMI range. 
Conclusions: Results support a causal role of higher BMI in increasing the risk of all-cause mortality and 
mortality from several specific causes.  
Key words: Body mass index, BMI, mortality, genetic epidemiology 
 
  
5 
 
INTRODUCTION 
Whilst severe obesity (body mass index [BMI]≥35kg/m2) increases the risk of death, having a 
BMI>25kg/m2 also increases the risk of all-cause mortality and mortality from vascular diseases, 
diabetes, respiratory diseases and cancer in a dose-response manner1-4. For example, each 5kg/m2 higher 
BMI (a transition between BMI categories) increased the risk of mortality by >30%, vascular mortality by 
40% and diabetic, renal and hepatic mortality by 60-120%1, 5. Additionally, ~3.6% of new adult cancer 
cases in 2012 (N~481,000; aged >30 after 10-years) were attributable to high BMI, a quarter of which 
could be attributed to rising BMI since 19826.  
However, there are inconsistencies within the literature relating to the “obesity paradox”, 
whereby being overweight can appear protective7, 8. Most prominently, in a systematic review and meta-
analysis (>2.88 million individuals), Flegal et al. showed ~6% lower risk of all-cause mortality in 
overweight (i.e., BMI 25.0-29.9kg/m2) compared to normal weight individuals (i.e., BMI 18.5-24.9kg/m2)7. 
Such controversial findings are not without limitation, as confounding by age, ill-health and lifestyle plus 
bias are likely9. Further, many studies report a characteristic J-shaped curve in the association between 
BMI and mortality1, 2, 5, 8, 10, where individuals at the lower tail of the BMI distribution (i.e., underweight 
[<18.5kg/m2] or below 22.5-24.9kg/m2) have an increased risk of mortality along with those above the 
‘normal weight’ threshold1, 2, 5. However, there are discrepancies in the reporting of this pattern, 
specifically between condition-specific mortality and in populations of varying ancestries3, 11-13.  
Mendelian randomization (MR) is a well-documented application of instrumental variable (IV) 
methodology using genetic variants (most commonly, single nucleotide polymorphisms [SNPs]) as IVs to 
provide relatively unbiased causal estimates of the effect of an exposure (i.e., BMI) on an outcome (i.e., 
mortality)14, 15. MR has provided evidence to support a causal effect of higher BMI increasing the risk of 
cardiovascular diseases (CVDs), diabetes, cardiometabolic traits and various cancers16-27. However, no 
study has explicitly used MR to explore the causal role of BMI in all-cause and cause-specific mortality. 
Here, data from the UK Biobank study, a powerful and large resource of comprehensive phenotypic, 
genetic and death registry data from the UK, were used to generate overall and sex-stratified estimates of 
the causal role of BMI in all-cause and cause-specific mortality. This approach was chosen to reduce 
problems of confounding and bias (e.g., reporting and recall bias) seen in traditional epidemiological 
studies.  
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METHODS 
The UK Biobank study 
UK Biobank recruited over 500,000 people aged 37-73 years (99.5% were 40-69 years) from the 
UK in 2006-2010. The study, participants and quality control (QC) have been described previously28-30. 
UK Biobank received ethical approval from the Research Ethics Committee (reference: 11/NW/0382). 
Details of BMI, mortality, covariables and genotyping are presented in the Supporting Information. At the 
time of this study (and after exclusions based on QC parameters for phenotypic and genetic data – 
Supporting Information, Figure S1), 335,308 participants of White British ancestry had valid BMI, genetic 
and survival data and 9,750 of these had died (Figure 1, Table S1 and Supporting Information).   
 
Statistical analysis 
 Cox proportional hazards regression models were used to estimate hazard ratios (HRs) for all-
cause and cause-specific mortality per unit increase (kg/m2) in BMI. The participant’s age was used as a 
measure of time; thus, models were adjusted for age. Analyses were conducted with two models: i) 
adjusted for secular trends (date of birth, DOB) and ii) additionally adjusted for current occupation, 
qualifications, smoking status, alcohol intake and physical activity. Analyses were restricted to the 
conditions responsible for a minimum number of deaths (>40)31 and performed in whole and sex-
stratified samples; therefore, results for all-cause mortality include all individuals who had died by the 
16th of February 2016 (N=9,750) but individual mortality causes presented may not equate to this 
number (Table S1 and Supporting Information).  
To generate the weighted genetic risk score (GRS) for MR analyses, the dosage of each genetic 
variant was weighted by its relative effect size on BMI reported by the Genetic Investigation of 
ANthropometric Traits (GIANT) consortium32 and summed across all variants (Table S2). The resulting 
total was rescaled by dividing by the sum of all effect sizes on BMI reported by the GIANT consortium32 
and multiplied by the number of genetic variants used; therefore, providing a variable reflecting the 
number of average BMI-increasing alleles each participant possessed33. The associations of the weighted 
GRS with BMI and of each covariable with BMI and the GRS were tested using linear regression and 
associations of each covariable with all-cause mortality was assessed using Cox proportional hazards 
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regression models. Associations with the GRS were adjusted for the first ten genetic principal components 
(PCs). 
For MR analyses, the instrumental variable ratio method was conducted. Firstly, BMI was 
regressed on a GRS comprising 77 SNPs (the denominator of the ratio method estimator) adjusted for the 
first ten genetic PCs. Secondly, Cox proportional hazards models were used to estimate the log(HR) of 
each mortality outcome per unit increase in the GRS (the numerator of the ratio method estimator) 
adjusted for secular trends (DOB) and the first ten genetic PCs. Exponentiating the resulting ratio of the 
numerator and denominator yielded a MR estimate of the HR of each mortality outcome per unit increase 
(kg/m2) in BMI (Box 1). Confidence intervals (CIs) were obtained using Taylor series expansions34. A 
simplification of the matrix-method for the Durbin-Wu-Hausman (DWH) test for endogeneity was used to 
compare the HR estimated from conventional Cox regression and MR (Supporting Methods). A priori, 
conclusions were based on effect estimates and their CIs, rather than using an arbitrary p-value 
threshold35. For example, given two effects with the same HR - one with narrow CIs, the other with wider 
CIs that included the null - both are described as showing the same effect, but one is more imprecisely 
estimated and should be treated with caution until replicated. All analyses were conducted using Stata 
v15. 
 
Linearity and proportional hazards assumption 
 Cubic spline models for both BMI (adjusted for variables in model (ii), described above) and the 
GRS (adjusted for secular trends (DOB) and the first ten genetic PCs) were plotted to test their pattern of 
association with mortality. Linearity tests were conducted after removing data below/above the 1st/99th 
percentile, respectively, due to the scarcity of data towards the tails of the BMI distribution. In addition, 
an approximate MR analogue to the non-linear plot of mortality against BMI was obtained by estimating 
localized average causal effects (i.e., MR estimates of the log-linear effect of BMI on mortality, adjusted for 
secular trends (DOB) and the first ten genetic PCs) within percentiles (the 5th, 10th, 25th, 50th, 75th and 85th 
percentile) of the instrument-free exposure (i.e., BMI that is orthogonal to the GRS)36. These localised 
average causal effects were joined and plotted against corresponding quantiles of the original exposure37. 
HRs were calculated relative to the mean BMI (27kg/m2) and CIs were obtained using bootstrapping 
(N=1000). Meta-regression was used to test for a linear trend in the GRS-BMI association (i.e., 
denominator of the ratio method) over quantiles of the instrument-free exposure.  
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To check the proportional hazards assumption, Schoenfeld residuals for BMI from the cubic 
spline models of each mortality outcome were tested for association with rank-normalised natural log of 
the follow-up time (age) using both Cox regression and MR (132 tests in the whole sample and sex-
stratified analyses for both methodologies) using Pearson’s correlation. If there was evidence for an 
association (using a Bonferroni-corrected alpha-level of 0.05/132=0.0004), an interaction term was fitted 
to the cubic spline model using the “tvc()” option in Stata. 
 
Sensitivity analysis 
Sensitivity analyses were conducted to (i) investigate the validity of the GRS as an IV using the 
MR-Egger38, weighted median and mode-based estimators39, compared to the inverse-variance weighted 
(IVW) method for two-sample MR38, 40; (ii) evaluate the impact of covariables associated with the GRS; 
and (iii) explore the sensitivity of the GRS by excluding genetic variants implicated as pleiotropic (N=7; 
leaving 70 SNPs, Table S3)17, 33. Details are presented in the Supporting Information.  
 
 
RESULTS 
 Included participants had an average age (at initial assessment) of 56.9 years (SD=8.0) and BMI 
of 27.4kg/m2 (SD=4.7) (Table 1). Of the 335,308 participants with required information for mortality 
analyses, 9,570 participants (N=5,882/3,688 males/females, respectively) had died by the 16th of 
February 2016 at an average age of 65.7 years old (SD=6.9) from various CVDs and cancers (Table 
S1a/1b).    
 
Observational analyses 
 Cox regression models provided evidence that BMI was associated with a higher risk of all-cause 
mortality (HR per 1kg/m2 higher BMI: 1.02; 95% CI: 1.02, 1.03) and mortality from CVD (HR: 1.07; 95% 
CI: 1.06, 1.08), specifically CHD (HR: 1.08; 95% CI: 1.06, 1.09) and those excluding CHD/stroke/aortic 
aneurysm (HR: 1.10; 95% CI: 1.08, 1.12), alongside mortality from overall cancer (HR: 1.01; 95% CI: 1.00, 
1.02) and cancers of the stomach (HR: 1.05; 95% CI: 1.01, 1.09), oesophagus (HR: 1.03; 95% CI: 1.00, 
1.06), kidney (HR: 1.07; 95% CI: 1.04, 1.11) and liver (HR: 1.05; 95% CI: 1.02, 1.09)(Table 2). There was 
evidence of an inverse association between BMI and lung cancer mortality (HR: 0.97; 95% CI: 0.95, 0.99). 
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There was also weak evidence to suggest that higher BMI marginally increased mortality from stroke, 
aortic aneurysm and cancers of the colorectum, pancreas and brain whilst decreasing mortality from 
respiratory diseases, bladder cancer, malignant melanoma and external causes (but estimates had wide 
CIs).  
In males, results were similar to the whole sample but with additional evidence for an association 
between higher BMI and decreased respiratory disease mortality (HR: 0.91; 95% CI: 0.88, 0.95), which 
was weaker in the overall sample; an increased prostate cancer mortality (HR: 1.05; 95% CI: 1.02, 1.08), 
alongside greater magnitudes of association of higher BMI with a decreased risk of mortality from lung 
cancer (HR: 0.94; 95% CI: 0.91, 0.97) and bladder cancer (HR: 0.93; 95% CI: 0.86, 1.00) and increased risk 
of mortality from oesophageal cancer (HR: 1.07; 95% CI: 1.03, 1.11) and liver cancer (HR: 1.08; 95% CI: 
1.03, 1.13) (Table 3). The estimate of association between BMI and brain cancer mortality was in the 
reverse direction to that obtained in the whole sample, but with wide CIs. 
In females, results were similar to those in the whole sample but with additional evidence for an 
association between higher BMI and an increased respiratory disease mortality (HR: 1.06; 95% CI: 1.02, 
1.10), the estimate of which was in the opposite direction in both the whole sample and males (Table 4). 
There was also evidence for an association between higher BMI and an increased risk of mortality from 
endometrial cancer (HR: 1.12; 95% CI: 1.07, 1.18) and both overall and post-menopausal breast cancer 
(HR: 1.02; 95% CI: 1.00, 1.04). There was no strong evidence of an association of BMI with lung cancer 
mortality and the estimate of association between higher BMI and oesophageal cancer mortality was in 
the opposite direction to that observed in the whole sample (HR: 0.87; 95% CI: 0.80, 0.95); however, all 
CIs overlapped.  
 
Association between the GRS and BMI 
 Each unit increase in the GRS (comprising 77 SNPs) in the UK Biobank participants of White 
British ancestry was associated with 0.111kg/m2 higher BMI (95% CI: 0.109, 0.114), explaining 1.8% of 
the variance and was slightly greater in females compared to males (Table 5).  
 
Covariable analysis 
Both BMI and mortality were associated with all covariables, including initial assessment age, 
sex, smoking status, alcohol consumption, qualifications, employment status and physical activity (Table 
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S4 and Table S5 for BMI and all-cause mortality, respectively). Unlike the direct measurement of BMI, the 
GRS was associated with covariables to a much lesser extent, with all estimates near zero (Table S6). 
 
MR analyses 
 Within the whole UK Biobank sample, MR analyses provided estimates of a similar or greater 
magnitude to observational analyses (with wider CIs), supporting the causal role of higher BMI in 
increasing the risk of all-cause mortality (HR: 1.03; 95% CI: 0.99, 1.07) and mortality from CVD (HR: 1.10; 
95% CI: 1.01, 1.19), specifically CHD (HR: 1.12; 95% CI: 1.00, 1.25) and those excluding 
CHD/stroke/aortic aneurysm (HR: 1.24; 95% CI: 1.03, 1.48), alongside mortality from stomach cancer 
(HR: 1.18; 95% CI: 0.87, 1.62) and oesophageal cancer (HR: 1.22; 95% CI: 0.98, 1.53) (Table 2). Although 
CIs were wide, the effect estimate for higher BMI on decreasing lung cancer mortality was consistent to 
that obtained in observational analyses (HR: 0.96; 95% CI: 0.85, 1.08). There was also evidence 
supporting the causal role of higher BMI in increasing mortality from external causes (HR: 1.30; 95% CI: 
1.05, 1.61), unlike the inverse association obtained in observational analyses (DWH P-value for 
comparison=0.01). In contrast, the effect estimates for higher BMI on mortality from cancer, kidney 
cancer and liver cancer were attenuated or in the opposite direction, with CIs too wide for conclusive 
interpretation (Table 2). 
 Results for males were similar to those in the whole sample, as estimates of the causal role of 
higher BMI in increasing the risk of all-cause mortality and mortality from all CVDs, stomach cancer, 
oesophageal cancer and kidney cancer, alongside the decreased risk of mortality from lung cancer and 
bladder cancer, were consistent to or greater than the observational analyses (Table 3). The effect 
estimates for higher BMI on mortality from respiratory diseases, cancer, prostate cancer and liver cancer 
were attenuated or in the opposite direction, with CIs too wide for conclusive interpretation (Table 3). 
 In females, the effect estimates of higher BMI increasing the risk of all-cause mortality and 
mortality from all CVDs were consistent to the observational analyses (Table 4). The effect estimates for 
higher BMI on the risk of mortality from breast cancer (HR: 0.83; 95% CI: 0.70, 0.99), specifically post-
menopausal breast cancer (HR: 0.84; 95% CI: 0.70, 1.00), endometrial cancer (HR: 0.63; 95% CI: 0.38, 
1.07) and external causes (HR: 1.79; 95% CI: 1.23, 2.58) were in the opposite direction to those obtained 
in observational analyses (DWH P-values=0.02, 0.03, 0.04 and 0.002, respectively). Furthermore, the 
effect estimates for higher BMI on mortality from respiratory diseases, overall cancer, oesophageal cancer 
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and kidney cancer were attenuated or in the opposite direction compared to observational analyses, but 
with CIs too wide for conclusive interpretation (Table 4). 
 Whilst there was some evidence for an observational relationship between higher BMI and 
mortality from other causes, CIs were too wide for conclusive interpretation in both adjusted 
observational and MR analyses, and with sex stratification (Table S7).  
 
Linearity and proportional hazards assumption 
The pattern of the GRS-mortality association appeared linear (Figure 2); however, the CIs were 
wide. The observational BMI-mortality relationship showed evidence of a J-shaped association (Figure 
3A). The J-shaped BMI-mortality association remained in MR analyses (Figure 3B), but with a smaller 
value of BMI at which mortality risk was lowest (~23kg/m2 vs. ~26kg/m2 with observational analyses) 
and apparently flatter over a larger BMI range. Meta-regression provided some evidence that the GRS-
BMI association was non-linear (P-value for linear trend=0.08 and P-value for heterogeneity <0.001). This 
was primarily driven by the extreme quantiles of BMI, as removal of these quantiles indicated a linear 
association (P-value for linear trend=0.999 and P-value for heterogeneity <0.001).  
 The proportional hazards assumption held for all mortality causes in both the conventional Cox 
regression and the MR analyses (Table S8a and S8b for observational and MR analyses, respectively).  
 
Sensitivity analyses 
 Across all methods, which assume linearity (including the IVW, MR-Egger, weighted median- and 
mode-based estimators), MR-derived estimates were consistent (Table S9a, S9b and S9c for whole 
sample, males and females, respectively). The MR-Egger intercept estimate showed some evidence for 
pleiotropy in the association between BMI and mortality from other cancers in the whole sample (Figure 
S2a) and males (Figure S2b), suggesting an underestimated MR estimate with negative directional 
pleiotropy (which was likely driven by the rs17024393 SNP). There was no strong evidence of directional 
pleiotropy in female-specific analyses (Table S9c).  
Additional adjustment for covariables made no substantive difference to the GRS-BMI association 
(Table S10a) and MR analyses (Table S10b). When excluding genetic variants implicated as pleiotropic 
(N=7; leaving 70 SNPs), there was no substantive difference in the GRS-BMI association (Table S11a) and 
MR analyses (Table S11b).  
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DISCUSSION 
Results supported the causal role of higher BMI in increasing the risk of all-cause mortality and 
mortality specifically from CVDs plus various cancers including oesophageal cancer and stomach cancer, 
as well as decreasing lung cancer mortality risk. Sex-stratified analyses were consistent with those in the 
whole sample and provided additional evidence for the causal role of higher BMI in increasing the risk of 
mortality from cancers of the kidney and liver in males and from external causes in females, whilst 
decreasing the risk of mortality from bladder cancer in males and breast cancer (specifically post-
menopausal breast cancer) and endometrial cancer in females. 
 The current results for the common mortality causes are consistent with previous studies1-5, 10. 
For example, the largest systematic review and meta-analysis of this relationship (including >30 million 
participants and ~3.7 million deaths) showed consistent evidence that each 5kg/m2 increment in BMI 
was associated with a 5% increased risk (95% CI: 4-7%) of all-cause mortality10. Concordant with this, 
scaling the current results in UK Biobank suggested that each 5kg/m2 increase in BMI was associated with 
a ~16% increased all-cause mortality risk (95% CI: -5%, 41%). Consistent with a collaborative analysis of 
>900,000 adults showing a ~40% increased risk of vascular mortality with each 5kg/m2 higher BMI1, 
scaling the current results to reflect the same increase in BMI implied a ~61% increased risk of overall 
CVD (95% CI: 1.07, 2.43) and ~76% increased risk of CHD (95% CI: 1.00, 3.11).  
For cancer, many MR-derived effect estimates were in the same direction as those derived from 
previous large-scale meta-analyses and reviews. For example, the association of BMI on incidence of 22 
cancer sites in 5.24 million individuals suggested linear positive relationships with cancers of the kidney, 
liver, colorectal and ovary and inverse associations with prostate, pre-menopausal breast cancer and lung 
cancer, the latter being strongly driven by smoking status11. Consistent with this, despite estimates from 
the Cox regression suggesting a positive association between BMI and prostate cancer mortality in UK 
Biobank, MR analyses provided evidence (with wide CIs) in the opposite direction (i.e., higher BMI 
reducing prostate risk). Additionally, in the Million Women Study, incrementally higher BMI was 
associated with an increased risk of mortality from cancers of the endometrium, oesophagus, kidney, 
pancreas, lymphatic system, ovary, breast cancer (in post-menopausal women) and colorectal cancer (in 
pre-menopausal women)3. Whilst there was observational evidence for a positive association on 
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mortality from endometrial cancer and post-menopausal breast cancer in the current study, estimates 
were inverse in MR analyses. However, analyses of cancer-specific mortality in the current study were 
limited by the rarity of these deaths (i.e., many cancers had <300 cases), which was accentuated further in 
sex-stratified analyses, where many estimates derived from MR analyses were opposite to those from 
observational analyses or had CIs too wide for interpretation. 
The association between BMI and all-cause mortality in MR analyses showed a J-shaped pattern 
but appeared flatter over a larger range of BMI compared to the observational association, with a smaller 
value of BMI at which mortality risk was lowest. This difference may be suggestive of confounding in 
previous observational associations, which overestimate the harmful effects of being underweight whilst 
underestimating the harmful effects of being overweight/obese. For example, studies using populations 
comprising older individuals with likely existing illnesses can generate spurious associations between 
lower BMI and increased risk of mortality (i.e., those who lose weight due to disease)9, 31, 41. Indeed, in the 
largest study to date, overestimation of estimates and this characteristic J-shaped association were 
reported greatest in analyses with the most potential for bias (including all participants; current, former 
or never smokers; and studies with short follow-up of <5 years), highlighting the importance for unbiased 
modes of estimation (such as those used here)10. Those that attempt to appropriately control for such 
effects (i.e., adjusting for baseline traits, restricting analyses to individuals who never smoked or had a 
longer follow-up), observe an emerging linear association2, 10, 42, 43. Whilst it is plausible that individuals 
considered severely and unhealthily underweight have a higher risk of mortality than those within the 
normal BMI range44, the current findings in this large population of healthy individuals support a more 
linear association, with lower BMI being protective over most of the observed range. Furthermore, the 
lowest risk of mortality occurred at approximately 23kg/m2 with MR, as opposed to being overweight 
(i.e., a BMI of 25.0-29.9kg/m2), which was observed in the current observational analyses, and has been 
implied previously by some existing observational studies7. Therefore, a stable BMI within the ‘normal’ 
range (i.e., 18.5-24.9kg/m2) may be the most beneficially healthy in reducing mortality risk, with any 
reduction within that range likely to be favourable5, 10.  
 The MR concept rests on several key assumptions14, 15: (i) the GRS must be associated with BMI; 
(ii) the GRS must be independent of the confounding factors that of the association between BMI and 
mortality; and (iii) there must be no independent pathway between the GRS and mortality other than 
through BMI – horizontal pleiotropy15. These assumptions were tested where possible and sensitivity 
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analyses conducted in the current study provided little evidence of confounding or pleiotropy and 
awarded greater confidence in the validity of the instrument used and, thus, MR-derived estimates. 
Notably, the GRS was associated (with very small effect sizes) with covariables. The sheer presence of an 
association between traditionally considered confounders with the GRS is interesting and could be due to 
(i) vertical pleiotropy (i.e., the GRS being associated with smoking status, for example, because of the 
potentially causal relationship between BMI and smoking) or (ii) co-incident genetic and phenotypic 
variation due to population structure or selection/collider bias; both reasons of which are increasingly 
easier to detect with the advent of very large studies such as UK Biobank45. Nevertheless, the magnitude 
of these relationships was marginal and MR analyses adjusting for these covariables were consistent with 
main analyses, suggesting little impact. Reverse causality is an important source of bias in observational 
estimates of the association between BMI and mortality and may be the driver of the characteristic J-
shaped association. Whilst it is possible that mortality may influence the relative distribution of genetic 
variants within a selected sample45, it is likely that this potential bias is less marked than that seen in 
observational studies. Whilst there are limitations to this current study, triangulation of different 
methodologies (each with orthogonal sources of bias) is important for drawing causal inference within 
this context and these findings add to the current body of evidence aiming to estimate the role played by 
BMI in mortality. 
The UK Biobank study is a unique opportunity to undertake these analyses, however, there are 
important aspects to consider. Firstly, current analyses were restricted to those of White British ancestry, 
limiting the generalisability of results to other ancestral groups. Secondly, one cannot rule the coincident 
structure in both genotype and phenotype out of any potential biasing role in genetic analyses within a 
study of this scale. Lastly, the power to detect associations with MR analyses remains low for many 
mortality causes even in a study comprising ~500,000 participants. Despite these, and given the 
incidence of the outcomes tested (where incidence of mortality from many causes will approximately 
double by 202228), UK Biobank provides a unique opportunity to analyse and revise these estimates 
further over the coming years. 
 
Conclusions  
This study represents the application of MR to assess the causal effect of higher BMI on the risk of 
mortality. Results supported the causal role of higher BMI in increasing the risk of all-cause mortality and 
15 
 
mortality from CVDs, various cancers and several specific causes. Alongside more large-scale, 
comprehensive studies and the application of robust causal inference methods that appropriately account 
for the heavy burden of confounding, reverse causation and bias within observational epidemiological 
designs, our results further highlight the need for a global effort to reduce the rising population trends for 
excess weight.  
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Table 1. Descriptive statistics for UK Biobank participants of White British Ancestry included in the main 
analyses 
Variable N Mean (SD) or percentage 
Age (years) at initial assessment  335,308 56.87 (8.00) 
Sex (% of males) 335,308 46.22 
Body mass index (kg/m2) 335,308 27.38 (4.74) 
Smoking status 334,142  
Never 183,170 54.82 
Former 117,838 35.27 
Current 33,134 9.92 
Alcohol drinker status 335,074  
Never 10,311 3.08 
Former 11,368 3.39 
Current 313,395 93.53 
Highest qualifications  275,544  
College or University degree 106,280 38.57 
A-levels 38,271 13.89 
O-levels 73,770 26.77 
CSEs 18,016 6.54 
NVQ/HND/HNC 22,012 7.99 
Other professional qualifications 17,195 6.24 
Current employment status 332,835  
In paid employment or self-employed 190,085 57.11 
Retired 117,615 35.34 
Looking after home/family 8,690 2.61 
Unable to work due to sickness/disability 9,982 3.00 
Unemployed 4,436 1.33 
Doing unpaid or voluntary work 1,404 0.42 
Full or part-time student 623 0.19 
Days/week spent doing vigorous physical activity 319,813 1.82 (1.94) 
Genotyping chip1 335,308 9.24 
Age at death (years) 9,570 65.66 (6.88) 
Date of death2 9,570 
06/02/2013 
(07/07/2007-16/02/2016) 
CSE = certificate of secondary education; HNC = higher national certificate; HND = higher national diploma; 
NVQ = national vocational qualification; SD = standard deviation 
1UK BiLEVE participants genotyped on the Affymetrix Axiom Array 
2Recorded as the mean (minimum and maximum) date of death 
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Table 2. Observational and MR analyses of all-cause and cause-specific mortality by BMI in UK Biobank participants of White British ancestry (men and women) 
Cause of death N1 
Observational 
MR-analyses DWH5 
Unadjusted Adjusted 
HR (95% CI)2 P-value HR (95% CI)3 P-value HR (95% CI)4 P-value  
All-cause6 9,570 1.03 (1.02, 1.03) 1.16x10-35 1.02 (1.02, 1.03) 1.20x10-14 1.03 (0.99, 1.07) 0.17 0.96 
Cardiovascular disease6 1,967 1.07 (1.06, 1.08) 1.67x10-65 1.07 (1.06, 1.08) 3.15x10-38 1.10 (1.01, 1.19) 0.04 0.62 
Coronary heart disease 1,087 1.07 (1.06, 1.09) 3.16x10-40 1.08 (1.06, 1.09) 1.35x10-25 1.12 (1.00, 1.25) 0.06 0.51 
Stroke 346 1.02 (1.00, 1.04) 0.12 1.01 (0.98, 1.04) 0.53 0.98 (0.80, 1.20) 0.84 0.70 
Aortic aneurysm 109 1.03 (0.99, 1.07) 0.10 1.03 (0.98, 1.08) 0.32 0.80 (0.56, 1.15) 0.23 0.17 
Other cardiovascular diseases 425 1.11 (1.09, 1.13) 1.19x10-40 1.10 (1.08, 1.12) 5.74x10-22 1.24 (1.03, 1.48) 0.02 0.23 
Respiratory diseases 532 1.00 (0.98, 1.01) 0.65 0.98 (0.96, 1.01) 0.19 1.03 (0.88, 1.22) 0.68 0.64 
Cancer6 5,613 1.01 (1.01, 1.02) 1.53x10-06 1.01 (1.00, 1.02) 0.01 0.99 (0.94, 1.04) 0.68 0.34 
Lung cancer 993 0.99 (0.97, 1.00) 0.10 0.97 (0.95, 0.99) 0.01 0.96 (0.85, 1.08) 0.49 0.62 
Colorectal cancer 552 1.01 (1.00, 1.03) 0.14 1.01 (0.99, 1.04) 0.18 1.06 (0.90, 1.25) 0.46 0.56 
Pancreatic cancer 388 1.01 (0.99, 1.03) 0.45 1.01 (0.99, 1.04) 0.34 1.10 (0.91, 1.33) 0.34 0.38 
Stomach cancer 144 1.06 (1.03, 1.09) 0.0003 1.05 (1.01, 1.09) 0.03 1.18 (0.87, 1.62) 0.29 0.48 
Oesophageal cancer 283 1.04 (1.01, 1.06) 0.002 1.03 (1.00, 1.06) 0.05 1.22 (0.98, 1.53) 0.08 0.15 
Malignant melanoma 119 1.00 (0.97, 1.04) 0.86 0.98 (0.93, 1.03) 0.38 1.18 (0.83, 1.66) 0.36 0.36 
Kidney cancer 181 1.08 (1.05, 1.11) 1.94x10-09 1.07 (1.04, 1.11) 3.41x10-05 0.93 (0.71, 1.23) 0.62 0.30 
Bladder cancer 101 1.02 (0.98, 1.06) 0.40 0.97 (0.92, 1.03) 0.33 0.79 (0.54, 1.15) 0.21 0.18 
Brain cancer 280 1.01 (0.99, 1.04) 0.37 1.01 (0.98, 1.04) 0.46 1.02 (0.81, 1.27) 0.89 0.97 
Liver cancer 169 1.07 (1.04, 1.10) 1.04x10-06 1.05 (1.02, 1.09) 0.005 0.99 (0.74, 1.32) 0.95 0.60 
Lymphatic cancer 528 1.00 (0.98, 1.02) 0.88 1.00 (0.98, 1.02) 0.87 1.04 (0.88, 1.22) 0.67 0.68 
Other cancers 755 1.00 (0.99, 1.02) 0.92 1.00 (0.98, 1.02) 0.87 0.95 (0.83, 1.09) 0.46 0.45 
External causes 306 0.99 (0.97, 1.01) 0.44 0.97 (0.95, 1.00) 0.07 1.30 (1.05, 1.61) 0.02 0.01 
BMI = body mass index; CI = confidence interval; DWH = Durbin-Wu-Hausman; HR = hazard ratio; MR = Mendelian randomization 
1Number of deaths from all causes or cause-specific mortality 
2Adjusted for secular trends (date of birth), estimates represent HR with each unit increase in BMI (kg/m2) 
3Adjusted for secular trends (date of birth), highest household occupation, education, smoking status, alcohol intake and physical activity 
4Adjusted for secular trends (date of birth) and the first ten genetic principal components  
5P-value for comparing estimates derived from observational and MR analyses using a simplification of the matrix method for DWH test statistic (see Supporting 
Methods) 
6Total number of UK Biobank participants who had died by 16th February 2016 from any cause (or those specifically defined as cardiovascular disease or cancer), which 
was stratified further into primary diseases of focus (excluding the mortality causes with fewer than 40 deaths and all other causes; see Table S1a and Supporting 
Information) 
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Table 3. Observational and MR analyses of all-cause and cause-specific mortality by BMI in male UK Biobank participants of White British ancestry 
Cause of death 
N1 
 
Observational 
MR-analyses 
DWH5 Unadjusted Adjusted 
HR (95% CI)2 P-value HR (95% CI)3 P-value HR (95% CI)4 P-value 
All-cause6 5,882 1.03 (1.02, 1.03) 4.00x10-18 1.02 (1.01, 1.03) 1.59x10-07 1.03 (0.98, 1.08) 0.26 0.93 
Cardiovascular disease6 1,467 1.08 (1.07, 1.09) 1.23x10-48 1.08 (1.06, 1.09) 7.39x10-28 1.09 (0.98, 1.20) 0.10 0.88 
Coronary heart disease 906 1.08 (1.07, 1.09) 8.84x10-32 1.08 (1.06, 1.10) 4.80x10-18 1.12 (0.98, 1.27) 0.09 0.62 
Stroke 194 1.03 (0.99, 1.06) 0.10 1.02 (0.98, 1.07) 0.29 1.01 (0.76, 1.33) 0.96 0.88 
Aortic aneurysm 83 1.04 (0.99, 1.09) 0.14 1.03 (0.97, 1.09) 0.40 0.80 (0.52, 1.21) 0.29 0.22 
Other cardiovascular diseases 284 1.11 (1.09, 1.14) 9.96x10-25 1.11 (1.08, 1.14) 9.99x10-15 1.16 (0.92, 1.45) 0.21 0.75 
Respiratory diseases 361 0.94 (0.91, 0.97) 1.08x10-05 0.91 (0.88, 0.95) 2.22x10-06 1.04 (0.85, 1.27) 0.71 0.32 
Cancer6 3,113 1.01 (1.00, 1.02) 0.002 1.01 (1.00, 1.02) 0.06 1.00 (0.93, 1.07) 0.98 0.72 
Lung cancer 571 0.96 (0.94, 0.98) 0.0002 0.94 (0.91, 0.97) 4.27x10-05 0.92 (0.78, 1.08) 0.29 0.57 
Prostate cancer 308 1.03 (1.01, 1.06) 0.01 1.05 (1.02, 1.08) 0.004 0.87 (0.70, 1.08) 0.21 0.12 
Colorectal cancer 329 1.03 (1.00, 1.05) 0.04 1.02 (0.99, 1.05) 0.23 1.09 (0.88, 1.34) 0.43 0.59 
Pancreatic cancer 201 1.01 (0.97, 1.04) 0.76 1.00 (0.96, 1.04) 0.97 1.18 (0.90, 1.54) 0.24 0.25 
Stomach cancer 105 1.07 (1.03, 1.11) 0.001 1.06 (1.01, 1.12) 0.02 1.15 (0.79, 1.68) 0.45 0.70 
Oesophageal cancer 226 1.06 (1.03, 1.09) 1.06x10-04 1.07 (1.03, 1.11) 1.17x10-04 1.28 (0.99, 1.65) 0.06 0.14 
Malignant melanoma 78 0.99 (0.94, 1.05) 0.85 0.97 (0.91, 1.04) 0.42 0.99 (0.64, 1.53) 0.96 0.98 
Kidney cancer 137 1.09 (1.05, 1.12) 8.27x10-07 1.08 (1.03, 1.13) 5.72x10-04 1.04 (0.75, 1.44) 0.82 0.79 
Bladder cancer 78 0.98 (0.93, 1.04) 0.58 0.93 (0.86, 1.00) 0.05 0.73 (0.47, 1.13) 0.16 0.18 
Brain cancer 169 1.01 (0.97, 1.05) 0.59 0.98 (0.94, 1.03) 0.47 1.15 (0.85, 1.54) 0.36 0.39 
Liver cancer 100 1.11 (1.07, 1.15) 3.18x10-08 1.08 (1.03, 1.13) 0.003 1.03 (0.70, 1.52) 0.86 0.73 
Lymphatic cancer 329 1.00 (0.97, 1.03) 0.91 1.01 (0.98, 1.04) 0.58 1.03 (0.83, 1.27) 0.81 0.79 
Other cancers 460 0.99 (0.96, 1.01) 0.22 1.00 (0.98, 1.03) 0.88 0.89 (0.74, 1.06) 0.20 0.26 
External causes 206 0.97 (0.94, 1.01) 0.12 0.97 (0.93, 1.01) 0.11 1.11 (0.85, 1.45) 0.44 0.32 
BMI = body mass index; CI = confidence interval; DWH = Durbin-Wu-Hausman; HR = hazard ratio; MR = Mendelian randomization 
1Number of deaths from all causes or cause-specific mortality 
2Adjusted for secular trends (date of birth), estimates represent HR with each unit increase in BMI (kg/m2) 
3Adjusted for secular trends (date of birth), highest household occupation, education, smoking status, alcohol intake and physical activity 
4Adjusted for secular trends (date of birth) and the first ten genetic principal components  
5P-value for comparing estimates derived from observational and MR analyses using a simplification of the matrix method for DWH test statistic (see Supporting 
Methods) 
6Total number of male UK Biobank participants who had died by 16th February 2016 from any cause (or those specifically defined as cardiovascular disease or cancer), 
which was stratified further into primary diseases of focus (excluding the mortality causes with fewer than 40 deaths and all other causes; see Table S1b and Supporting 
Information)  
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Table 4. Observational and MR analyses of all-cause and cause-specific mortality by BMI in female UK Biobank participants of White British ancestry 
Cause of death N1 
Observational 
MR-analyses 
DWH5 Unadjusted Adjusted 
HR (95% CI)2 P-value HR (95% CI)3 P-value HR (95% CI)4 P-value 
All-cause6 3,688 1.02 (1.01, 1.03) 1.84x10-11 1.02 (1.01, 1.02) 3.10x10-05 1.03 (0.96, 1.09) 0.42 0.90 
Cardiovascular disease6 500 1.06 (1.04, 1.08) 6.64x10-14 1.06 (1.04, 1.08) 1.55x10-08 1.12 (0.95, 1.32) 0.19 0.53 
Coronary heart disease 181 1.06 (1.03, 1.09) 5.05x10-06 1.08 (1.04, 1.12) 6.87x10-06 1.12 (0.85, 1.47) 0.43 0.71 
Stroke 152 1.01 (0.97, 1.04) 0.75 1.00 (0.95, 1.04) 0.84 0.95 (0.70, 1.28) 0.72 0.70 
Other cardiovascular diseases 141 1.11 (1.08, 1.14) 2.01x19-17 1.10 (1.06, 1.13) 8.41x10-09 1.42 (1.04, 1.93) 0.03 0.12 
Respiratory diseases 171 1.05 (1.02, 1.08) 0.0004 1.06 (1.02, 1.10) 0.002 1.02 (0.77, 1.36) 0.88 0.86 
Cancer6 2,500 1.01 (1.00, 1.02) 0.01 1.01 (1.00, 1.02) 0.20 0.98 (0.91, 1.05) 0.52 0.35 
Lung cancer 422 1.01 (0.99, 1.03) 0.53 1.00 (0.97, 1.03) 0.97 1.02 (0.85, 1.22) 0.86 0.91 
Breast cancer 468 1.02 (1.00, 1.03) 0.05 1.02 (1.00, 1.04) 0.13 0.83 (0.70, 0.99) 0.03 0.02 
Pre-menopausal 48 1.00 (0.95, 1.06) 0.94 1.00 (0.95, 1.06) 0.90 0.77 (0.45, 1.32) 0.35 0.34 
Post-menopausal 420 1.02 (1.00, 1.04) 0.04 1.02 (1.00, 1.04) 0.13 0.84 (0.70, 1.00) 0.05 0.03 
Colorectal cancer 223 0.99 (0.97, 1.02) 0.59 1.01 (0.98, 1.04) 0.73 1.02 (0.80, 1.31) 0.85 0.80 
Pancreatic cancer 187 1.01 (0.98, 1.04) 0.57 1.02 (0.99, 1.05) 0.27 1.02 (0.78, 1.34) 0.88 0.93 
Ovarian cancer 211 1.00 (0.97, 1.02) 0.76 1.00 (0.96, 1.03) 0.82 1.19 (0.92, 1.53) 0.19 0.17 
Endometrial cancer 50 1.10 (1.06, 1.15) 3.29x10-06 1.12 (1.07, 1.18) 1.23x10-05 0.63 (0.38, 1.07) 0.09 0.04 
Oesophageal cancer 57 0.95 (0.90, 1.01) 0.10 0.87 (0.80, 0.95) 0.001 1.04 (0.64, 1.70) 0.87 0.71 
Malignant melanoma 41 1.00 (0.94, 1.06) 0.95 0.97 (0.90, 1.04) 0.40 1.61 (0.91, 2.87) 0.10 0.10 
Kidney cancer 44 1.08 (1.03, 1.13) 0.002 1.06 (1.00, 1.13) 0.06 0.67 (0.38, 1.17) 0.16 0.09 
Brain cancer 111 1.00 (0.97, 1.04) 0.80 1.03 (0.99, 1.07) 0.19 0.85 (0.60, 1.21) 0.36 0.34 
Liver cancer 69 1.03 (0.99, 1.08) 0.18 1.03 (0.97, 1.09) 0.34 0.94 (0.60, 1.46) 0.77 0.67 
Lymphatic cancer 199 1.00 (0.97, 1.02) 0.76 0.98 (0.94, 1.01) 0.21 1.05 (0.81, 1.37) 0.70 0.68 
Other cancers 295 1.01 (0.98, 1.03) 0.52 0.99 (0.96, 1.02) 0.60 1.04 (0.84, 1.29) 0.71 0.76 
External causes 100 0.99 (0.95, 1.03) 0.72 0.96 (0.91, 1.01) 0.09 1.79 (1.23, 2.58) 0.002 0.002 
BMI = body mass index; CI = confidence interval; DWH = Durbin-Wu-Hausman; HR = hazard ratio; MR = Mendelian randomization 
1Number of deaths from all causes or cause-specific mortality 
2Adjusted for secular trends (date of birth), estimates represent HR with each unit increase in BMI (kg/m2) 
3Adjusted for secular trends (date of birth), highest household occupation, education, smoking status, alcohol intake and physical activity 
4Adjusted for secular trends (date of birth) and the first ten genetic principal components  
5P-value for comparing estimates derived from observational and MR analyses using a simplification of the matrix method for DWH test statistic (see Supporting 
Methods) 
6Total number of female UK Biobank participants who had died by 16th February 2016 from any cause (or those specifically defined as cardiovascular disease or cancer), 
which was stratified further into primary diseases of focus (excluding the mortality causes with fewer than 40 deaths and all other causes; see Table S1b and Supporting 
Information)  
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Table 5. Association between weighted GRS (comprising 77 SNPs) and BMI in UK Biobank participants of 
White British ancestry 
Sample 
N 
Effect estimate 
(95% CI)1 
P-value R2 (%)2 
Whole sample 335,308 0.111 (0.109 0.114) <1.20x10-307 1.82 
Males  154,967 0.105 (0.101, 0.109) <1.20x10-307 2.06 
Females 180,341 0.117 (0.112, 0.121) <1.20x10-307 1.70 
BMI = body mass index; CI = confidence interval; GRS = genetic risk score; SNP = single nucleotide 
polymorphism 
1Effect estimate (and corresponding P-value) represents the change in BMI (kg/m2) per BMI-increasing 
allele in individuals of White British ancestry adjusted for the first ten genetic principal components 
2Variance in BMI explained by the GRS 
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FIGURE LEGENDS 
Figure 1. Flow-chart of those included in main analyses 
BMI = body mass index 
1Of those with valid BMI, genetic and survival data, 335,308 were of White British ancestry 
2Of those who had died by the 16th February 2016, 9,570 were of White British ancestry. 
 
Figure 2. Assessment of linearity in associations of the GRS (comprising 77 SNPs) and all-cause 
mortality in the UK Biobank sample of White British ancestry  
CI = confidence intervals; GRS = genetic risk score; SNPs = single nucleotide polymorphisms 
Association between the GRS (comprising 77 SNPs) and all-cause mortality, adjusted for secular trends (date 
of birth) and the first ten genetic principal components. Linearity tests were conducted after removing data 
below/above the 1st/99th percentile of BMI, respectively, due to the scarcity of data towards the tails of the 
BMI distribution. Hazard ratios (HRs) were calculated relative to the mean GRS value with 1000 bootstrap 
resamples to obtain 95% confidence intervals (CIs). The black lines represent the fitted HRs from cubic spline 
models (with the mean value of the GRS as the reference). 
 
Figure 3. Assessment of linearity in associations of BMI and all-cause mortality in the UK Biobank 
sample of White British ancestry using BMI (A) and instrument-free BMI (B). 
BMI = body mass index; CI = confidence intervals 
A: Observational associations between BMI and all-cause mortality obtained using conventional Cox 
regression (adjusted for secular trends (date of birth), current occupation, qualifications, smoking status, 
alcohol intake and physical activity).  
B: An approximate analogue using MR stratified by categories of the instrument-free exposure (divided at 
the 5th, 10th, 25th, 50th, 75th and 85th percentile) adjusted for secular trends (date of birth) and first ten 
genetic principal components. These localised average causal effects were then joined together and plotted 
against the corresponding percentiles of the original exposure. Linearity tests were conducted after 
removing data below/above the 1st/99th percentile, respectively, due to the scarcity of data towards the tails 
of the BMI distribution. Hazard ratios (HRs) were calculated relative to the mean BMI (27kg/m2), with 1000 
bootstrap resamples to obtain 95% confidence intervals (CIs). The darker lines represent the fitted HRs from 
cubic spline models (with mean BMI as the reference). 
Figure 1.  
 
 
UK Biobank phenotype dataset 
(N=502,619) 
Height measured at initial 
assessment (N=500,080) 
Invalid height measures (N=14) 
Valid height measures from initial 
assessment (N=500,066) 
Available BMI measures 
(N=499,504) 
No weight measures (N=562) 
Additional impedance measures of 
BMI (N=255) 
Difference between BMI 
impedance measure (N=1,164) 
Valid BMI measures (N=498,595) 
Valid BMI with plausible age and 
death data (N=498,584) 
Implausible/missing age and death 
information (N=11) 
Valid BMI, genetic and survival 
data (N=404,753)1 
Deaths until 16th February 2016 
for main analyses (N=11,161)2 
Missing genetic data (N=14,070) 
Those also with available genetic 
data (N=484,514) 
Recommended exclusions and 
related individuals (N=79,761) 
Figure 2. 
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Figure 3.  
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Box: Mendelian randomization in the context of survival analyses 
Mendelian randomization (MR) is a well-documented method that uses genetic variation (most 
commonly, single nucleotide polymorphisms [SNPs] or a genetic risk score [GRS] comprising multiple 
SNPs) as a proxy for an exposure of interest in an instrumental variable analysis to provide an unbiased 
and unconfounded causal estimate of the effect of the exposure (here, body mass index [BMI]) on an 
outcome (here, mortality). MR relies on three key assumptions (i) the instrument (Z) is associated with the 
exposure (X); (ii) the instrument is independent of confounding factors (C) of the association between the 
exposure (X) and outcome (Y); and (iii) there must be no independent pathway between the instrument 
(Z) and outcome (Y) other than through exposure (X) – horizontal pleiotropy – (see Figure below).  
 
 
 
 
 
 
The first MR studies used data from large-scale cohorts and consortia that had available genetic, 
exposure and outcome data in one sample, where the causal estimate could be calculated in a variety of 
ways1. However, having all information available for MR analyses (genetic, exposure and outcome data) 
within one sample is difficult in large enough samples for adequate statistical power. More recently, and 
with the rise in genome-wide association studies (GWAS), two-sample MR methods have been developed 
to overcome the necessity of having all information within one sample and have proved useful in situations 
where both genetic and exposure data are present in one sample and both genetic and outcome data are 
present in a second sample. Here, the causal estimate can be calculated in a variety of ways, each of which 
has different assumptions and provides the ability to test the validity of the MR estimate:  
- Inverse variance weighted2 
- Weighted median- and mode-based estimators3,4  
- MR-Egger regression5 
Whilst MR is an established technique within population health sciences, the application in longitudinal 
studies and survival analyses is new; therefore, there is no ‘gold standard’. For this manuscript, the 
instrumental variable ratio estimate was used in primary analyses, separating out the analyses that 
generated the numerator and denominator: 
 
𝛽𝐼𝑉 = 𝛽𝑌𝑍/𝛽𝑋𝑍 
 
where 𝛽𝐼𝑉 is the instrumental variable causal estimate of the association between BMI and mortality; 𝛽𝑌𝑍  
(numerator) is the log hazard ratio (HR) of each mortality outcome (𝑌) with each unit increase in a GRS (𝑍) 
derived from the Cox proportional hazards model and 𝛽𝑋𝑍 (denominator) is the change in BMI (𝑋) with 
each unit increase in the GRS (𝑍). Exponentiating the resulting ratio of the numerator and denominator 
yielded a MR estimate of the HR of each mortality outcome per unit increase (kg/m2) in BMI. For primary 
analyses in the current study, the instrument used was a GRS comprising 77 SNPs associated with BMI 
reported in the Genetic Investigation of ANthropometric Traits (GIANT) consortium. The GRS was 
generated in UK Biobank by weighting the genetic dosage of each of the 77 SNPs by its relative effect size 
reported in the GIANT consortium, then summed across all SNPs, divided by the combined effect size of all 
SNPs and multiplied by the number of SNPs available (N=77). The GRS therefore represented the number 
of average BMI-increasing variants that each individual possessed. In sensitivity analyses in this study, each 
of the 77 SNPs was used individually and combined using the various two-sample MR techniques (inverse 
variance weighted, weighted median, weighted mode and the MR-Egger estimators) to test the validity of 
MR assumptions. 
 
For more detail on each method discussed, see the following published articles: 
1) One-sample MR methods: Haycock et al. Best (but oft-forgotten practices: the design, analysis and interpretation 
of Mendelian randomization studies. The American Journal of Clinical Nutrition 2016; 103(4): 965-978. 
2) Inverse-variance weighted: Burgess et al. Mendelian randomization analysis with multiple genetic variants using 
summarized data. Genetic Epidemiology 2013; 37(7): 658-665. 
3) Weighted median: Bowden et al. Consistent estimation in Mendelian randomization with some invalid instruments 
using a weighted median estimator. Genetic Epidemiology 2016; 40(4): 304-314. 
4) Weighted mode: Hartwig et al. Robust inference in summary data Mendelian randomization via the zero modal 
pleiotropy assumption. International Journal of Epidemiology 2017; 46(6): 1985-1998.  
5) MR-Egger: Bowden et al. Mendelian randomization with invalid instruments; effect estimation and bias detection 
through Egger regression. International Journal of Epidemiology 2015; 44(2): 512-525. 
